Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-11
1999-12-21
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
060049677
ABSTRACT:
This invention is directed to methods and compositions for treating hyperproliferative skin disorders utilizing a quinazoline derivative as an active ingredient.
REFERENCES:
patent: 5457105 (1995-10-01), Barker
Ben-Bassat, et al., "Tyrphostins Suppress the Growth of Psoriatic Keratinocytes" Exper. Dermatol., 4(2):82-84 (1995).
Ben-Basset et al., "Inhibitors of Epidermal Growth Factor Receptor Kinase and Cyclin Dependent Kinase 2 Activation Induce Growth Arrest, Differentiation, and Apoptosis of Human Papilloma Virus 16-Immortalized Human Keratinocytes", Cancer Research, vol. 57:3741-3750 (1997).
Broker and Botchan, "Papillomaviruses: Retrospectives and Prospectives," Cancer Cells-DNA Tumor Viruses, New York: Cold Spring Harbor Laboratory (1986).
Bronaugh, "Preparation of Biological Membranes", In: Methods for Skin Absorption, pp. 61-66. Ed. Barbara Kempanien and William G. Reifenrath, CRC Press (1990).
Decker and Lohmann-Matthes, "A Quick and Simple method for the Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular Cytotoxicity and Tumor Necrosis Factor (TNF) Activity", J. Immunol. Methods 15:61-69 (1988).
Durst, et al., "Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA," Oncogene, 1:251-256 (1987).
Dvir et al., "The Inhibition of EGF-dependent Proliferation of Keratinocytes by Tyrphostin Tyrosine Kinase Blockers," J. Cell Biol. 113:857-865 (1991).
Elder, et al., "Overexpression of Transforming Growth Factor .alpha. in Psoriatic Epidermis," Science, 243:811-814 (1989).
Ellis et al., "Melanoma, Growth Factors, Acanthosis Nigricans, the Sign of Leser-Trelat, and Multiple Acrochordons," N. Engl. J. Med. 317:1582-1587 (1987).
Fendley et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product," Cancer Research 50:1550-1558 (1990).
Gazit, et al., "Tyrophostins IV-Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4-Anilidoquinazolines," Biorg. Med. Chem. 4:1203-1207 (1996).
Gottlieb, et al., "Detection of Transforming Growth Factor .alpha. In Normal, Malignant, and Hyperproliferative Human Keratinocytes," J. Exp. Med., 167:670-675 (1988).
Green et al., "Differences in Human Skin Between the Epidermal Growth Factor Receptor Distribution Detected by EGF Binding and Monoclonal Antibody Recognition," J. Invest. Dermatol. 85:239-245 (1985).
Grossman, et al., "Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes," Proc. Natl Acad Sci USA, 86:6367-6371 (1989).
Hagedorn, M. and T. Baukrecht, "Evidence of EGF like Factors (EGF-F) in Different Skin Tumors," Z. Hautkr 65(6):575-577 (1990) GERMAN.
Kawamoto, T., et al. "Relation of Epidermal Growth Factor Receptor Concentration to Growth of Human Epidermoid Carcinoma A431 Cells," J. Biol. Chem. 259(12):7761-7766 (1984).
Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity," J. Immunol. Methods 64:313-320 (1983).
Krane, et al., "Synergistic Effects of Epidermal Growth Factor (EGF) and Insulin-Like Growth Factor I/Somatomedin C (IGF-I) on Keratinocyte Proliferation may Be Mediated by IGF-I Transmodulation of the EGF Receptor," J. Invest. Dermatol., 96:419-424 (1991).
Krane, et al., "The Insulin-like Growth Factor I Receptor is Overexpressed in Psoriatic Epidermis, but Is Differentially Regulated from the Epidermal Growth Factor Receptor," J. Exp. Med., 175:1081-1090 (1992).
Krueger, et al., "Role of Growth Factors, Cytokines, and Their Receptors in the Pathogenesis of Psoriasis," J. Invest. Dermatol., 94:1355-1405 (1990).
Kumar et al., "A Simple Microwave Technique for the Separation of Epidermis and Dermis in Skin Uptake Studies," Pharmaceutical Res. 6:740-741 (1989).
Levitzki, "Signal-Transduction Therapy", Eur. J. Biochem., vol. 226, No. 1:1-13 (1994).
Levitzki, "Receptor Activation by Antigens, Cytokines, Hormones and Growth Factors", Annals of the New York Academy of Sciences, vol. 766:363-368 (1995).
Mossman, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Methods 65:55-63 (1983).
Nanney et al., "Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages," J. Invest. Dermatol. 83(5):385-393, 1984; Green et al., J. Invest. Dermatol. 85:239-245 (1985).
Nanney, et al., "Altered [.sup.125 I] Epidermal Growth Factor Binding and Receptor Distribution in Psoriasis," J. Invest. Dermatol., 86(3):260-265 (1986).
Nanney, et al., "Modulation of Epidermal Growth Factor Receptors in Psoriatic Lesions During Treatment with Topical EGF," J. Invest. Dermatol., 98:296-301 (1992).
Parkin, et al., "Estimates of the Worldwide Frequency of Sixteen Major Cancers in 1980," Cancer, 41:184-187 (1988).
Pfister, "Biology and Biochemistry of Papillomaviruses," Rev. Phys. Biochem. Pharmacol., 99:111-181 (1984).
Traxler et al., "4-Phenylamino(pyrrolopyrimidines): Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase", J. Med. Chem, vol. 39, No. 12:2285-2292 (1996).
Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," Cell 61:203-212 (1990).
Vassar, et al., "Transgenic mice provide new insights into the role of TGF-.alpha. during epidermal development and differentiation," Genes and Develop., 5:714-727 (1991).
Weinstein, et al., "Cell Kinetic Basis for Pathophysiology of Psoriasis," J. Invest. Dermatol., 85:579 (1985).
Wright and Camplejohn, Eds., Psoriasis: Cell Proliferation, (Churchill Livingstone, Edinburgh, 1983), pp. 147-295.
Zur Hausen, "Herpes Simplex Virus in Human Genital Cancer," Int. Rev. Exp. Path., 25:307-326 (1983).
Bridges, et al., "Tyrosine Kinase Inhibitors. 8. An Unusually Step Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-Dimethoxyquinazolin e (PD153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor," J. Med. Chem. 39:267-76 (1996).
Hirth Klaus Peter
McMahon Gerald
Narog Blair
Shawver Laura
Tang Peng Cho
Henley III Raymond
Sugen Inc.
LandOfFree
Psoriasis treatment with quinazoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Psoriasis treatment with quinazoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Psoriasis treatment with quinazoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-505423